RSS

Spark Therapeutics

Pfizer and Spark Therapeutics have announced that the Phase III programme for the investigational haemophilia B gene therapy is to be initiated by Pfizer. more

News

US-based company, Spark Therapeutics, has announced a programme of improved access to its one-time gene therapy treatment, LUXTURNA, indicated for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy more

News